Skip to main content

Table 1 Clinical–pathological features of experimental autoimmune encephalitis mice and treatment groups

From: Comparison of human adult stem cells from adipose tissue and bone marrow in the treatment of experimental autoimmune encephalomyelitis

Treatment

Disease onset,DPI (range)

Disease incidence, n/n total (%)

Mean maximum score (range)

Cumulative disease score

Inflammatory area (%)

Demyelinated area (%)

Axonal loss (%)

Control

9.0 ± 1.0 (7 to 10)

12/12 (100)

3.5 ± 0.5 (3 to 4)

30.4 (±9.57)

14.62 ± 6.6

0.68 ± 0.3†

6.1 ± 2.0†

BMSC

10.9 ± 1.9 (8 to 13)

10/10 (100)

2.3 ± 1.1 (1 to 4)

14.2 ± 11.8

7.3 ± 4.9

0.91 ± 0.3

1.5 ± 0.9

ASC

9.7 ± 0.9 (9 to 15)

9/12 (75)

2.6 ± 0.7 (1 to 4)

16.1 ± 7.2*

5.1 ± 4.8

0.75 ± 0.2

1.3 ± 1.5

SVF

9.3 ± 1.6 (2 to 3)

10/12 (83)

2.6 ± 0.7 (1 to 4)

10.8 ± 6.4*

6.7 ± 4.4

0.76 ± 0.2

3.1 ± 0.9

  1. ASC, adipose stem cell; BMSC, bone-derived marrow stromal cell; DPI, days post disease induction; SVF, stromal vascular fraction. *P ≤ 0.05 between control group and ASC-treated group and SVF-treated group. †P ≤ 0.05 between control group and experimental groups.